These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 34889301)

  • 1. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
    Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
    Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
    Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
    Front Immunol; 2022; 13():984132. PubMed ID: 36189265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.
    Lopez AT; Geskin L
    Oncologist; 2018 Oct; 23(10):1119-1126. PubMed ID: 30018132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect.
    Grimaux X; Delva R; Jadaud E; Croue A
    Australas J Dermatol; 2019 Aug; 60(3):e235-e236. PubMed ID: 30592031
    [No Abstract]   [Full Text] [Related]  

  • 5. Concomitant nivolumab-associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma.
    Khazaeli M; Grover R; Pei S
    J Cutan Pathol; 2023 Jun; 50(6):520-523. PubMed ID: 36601731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature.
    Anastasopoulou A; Papaxoinis G; Diamantopoulos P; Christofidou E; Benopoulou O; Stratigos A; Gogas H
    J Immunother; 2018 Apr; 41(3):164-167. PubMed ID: 29309291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bullous pemphigoid associated with the 480-mg nivolumab dose in a patient with metastatic renal cell carcinoma.
    Palla AR; Smith E; Doll D
    Immunotherapy; 2019 Oct; 11(14):1187-1192. PubMed ID: 31462105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
    Chalmers JR; Wojnarowska F; Kirtschig G; Mason J; Childs M; Whitham D; Harman K; Chapman A; Walton S; Schmidt E; Godec TR; Nunn AJ; Williams HC
    Health Technol Assess; 2017 Mar; 21(10):1-90. PubMed ID: 28406394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid.
    Sowerby L; Dewan AK; Granter S; Gandhi L; LeBoeuf NR
    JAMA Dermatol; 2017 Jun; 153(6):603-605. PubMed ID: 28355425
    [No Abstract]   [Full Text] [Related]  

  • 10. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
    Aggarwal P
    Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
    [No Abstract]   [Full Text] [Related]  

  • 11. Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review.
    de Lorenzi C; André R; Vuilleumier A; Kaya G; Abosaleh M
    Ann Dermatol Venereol; 2020 Mar; 147(3):221-227. PubMed ID: 31982173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid.
    Sadik CD; Langan EA; Grätz V; Zillikens D; Terheyden P
    Front Immunol; 2019; 10():1934. PubMed ID: 31474998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
    Cosimati A; Rossi L; Didona D; Forcella C; Didona B
    J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab.
    Bruni M; Moar A; Schena D; Girolomoni G
    Dermatol Online J; 2022 Mar; 28(2):. PubMed ID: 35670683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
    Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
    BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab-induced localized genital bullous pemphigoid in a 60-year-old male.
    Alvarado SM; Weston G; Murphy MJ; Stewart CL
    J Cutan Pathol; 2022 May; 49(5):468-471. PubMed ID: 34881446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Case of Bullous Pemphigoid Associated With Nivolumab Therapy.
    Gotera N; Weilg P; Heleno C; Ferrari-Gabilondo N
    Cureus; 2022 May; 14(5):e24804. PubMed ID: 35686260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab-induced lichen planus.
    Yilmaz M; Mese SG; Celik U
    J Oncol Pharm Pract; 2020 Apr; 26(3):758-760. PubMed ID: 31382865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer.
    Fujiwara R; Inamura K; Yuasa T; Numao N; Yamamoto S; Masuda H; Kawauchi A; Takeuchi K; Yonese J
    Int J Clin Oncol; 2020 Jan; 25(1):151-157. PubMed ID: 31522314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab.
    Olsen E; Svoboda SA; Saikaly SK; Missall TA; Motaparthi K
    Cureus; 2023 Aug; 15(8):e43230. PubMed ID: 37692698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.